Yu Yao

14PUBLICATIONS
148CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 08, 2026
FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate.

|Jan 13, 2026
Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights.

Allison L Brodsky, Amma Asare, Bryan Fellman

|Sep 18, 2025
KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer.

Yongkun Wei, Minghui Liu, Er-Yen Yen

|Mar 29, 2024
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers.

Guang Lei, Chao Mao, Amber D Horbath

|Jul 21, 2023
Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer.

Xudong Zhang, Jun Yao, Xiaoran Li

|Feb 01, 2023
Tumor-associated nonmyelinating Schwann cell-expressed <i>PVT1</i> promotes pancreatic cancer kynurenine pathway and tumor immune exclusion.

Chengcao Sun, Youqiong Ye, Zhi Tan

Pageof 3

Frequent Collaborators

5 joint publications

Mien-Chie Hung

4 joint publications

Leng Han

4 joint publications

Dihua Yu

3 joint publications

Yajuan Li